PE20212070A1 - Moduladores de trex1 - Google Patents
Moduladores de trex1Info
- Publication number
- PE20212070A1 PE20212070A1 PE2021000822A PE2021000822A PE20212070A1 PE 20212070 A1 PE20212070 A1 PE 20212070A1 PE 2021000822 A PE2021000822 A PE 2021000822A PE 2021000822 A PE2021000822 A PE 2021000822A PE 20212070 A1 PE20212070 A1 PE 20212070A1
- Authority
- PE
- Peru
- Prior art keywords
- trex1
- hydroxyn
- dihydropyrimidine
- isoxazol
- carboxamide
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Amplifiers (AREA)
- Apparatus For Radiation Diagnosis (AREA)
- Magnetic Resonance Imaging Apparatus (AREA)
- Burglar Alarm Systems (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Referido a un compuesto que tiene la Formula I o una sal farmaceuticamente aceptable de este, en donde: R1 y R2 son H, alquilo(C1-C4), haloalquilo(C1-C4), entre otros; X es un enlace, NR3 , O, S, o alquileno(C1-C4); el anillo A es fenilo, heteroarilo de 5 a 6 miembros, heterociclilo de 4 a 7 miembros, entre otros. Entre los compuestos preferidos tenemos los siguientes: 2-ciclobutil-5-hidroxiN-(isoxazol-4-il)-1- metil-6-oxo-1,6- dihidropirimidin-4- carboxamida; 2-(5-bromo-2- metilfenil)-5-hidroxiN-(isoxazol-4-il)-1- metil-6-oxo-1,6- dihidropirimidin-4- carboxamida; entre otros. Estos compuestos modulan TREX1 (Tres exonucleasas 1 de reparacion principal) y se emplean en el tratamiento del cancer.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862776031P | 2018-12-06 | 2018-12-06 | |
| PCT/US2019/064825 WO2020118133A1 (en) | 2018-12-06 | 2019-12-06 | Modulators of trex1 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20212070A1 true PE20212070A1 (es) | 2021-10-26 |
Family
ID=69024702
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2021000822A PE20212070A1 (es) | 2018-12-06 | 2019-12-06 | Moduladores de trex1 |
Country Status (28)
| Country | Link |
|---|---|
| US (1) | US20220017502A1 (es) |
| EP (1) | EP3891145B1 (es) |
| JP (1) | JP7471297B2 (es) |
| KR (1) | KR20210102310A (es) |
| CN (1) | CN113396149B (es) |
| AU (1) | AU2019395005A1 (es) |
| BR (1) | BR112021010919A2 (es) |
| CA (1) | CA3122093A1 (es) |
| CL (1) | CL2021001461A1 (es) |
| CO (1) | CO2021008816A2 (es) |
| CY (1) | CY1126082T1 (es) |
| DK (1) | DK3891145T3 (es) |
| EA (1) | EA202191519A1 (es) |
| ES (1) | ES2949999T3 (es) |
| FI (1) | FI3891145T3 (es) |
| HR (1) | HRP20230701T1 (es) |
| HU (1) | HUE062866T2 (es) |
| IL (1) | IL283672B1 (es) |
| LT (1) | LT3891145T (es) |
| MA (1) | MA54386B1 (es) |
| MX (1) | MX2021006695A (es) |
| PE (1) | PE20212070A1 (es) |
| PL (1) | PL3891145T3 (es) |
| PT (1) | PT3891145T (es) |
| RS (1) | RS64336B1 (es) |
| SG (1) | SG11202105772SA (es) |
| SI (1) | SI3891145T1 (es) |
| WO (1) | WO2020118133A1 (es) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3147419A1 (en) * | 2019-07-23 | 2021-01-28 | Constellation Pharmaceuticals, Inc. | Modulators of trex1 |
| WO2022031640A1 (en) * | 2020-08-04 | 2022-02-10 | Wake Forest University Health Sciences | Trex1 inhibitors and uses thereof |
| IL308016A (en) * | 2021-04-26 | 2023-12-01 | Constellation Pharmaceuticals Inc | Modulators of TREX1 |
| BR112023022917A2 (pt) * | 2021-05-05 | 2024-01-23 | Constellation Pharmaceuticals Inc | Moduladores de trex1 |
| WO2023137030A1 (en) * | 2022-01-11 | 2023-07-20 | Constellation Pharmaceuticals, Inc. | Modulators of trex1 |
| WO2023156386A2 (en) * | 2022-02-16 | 2023-08-24 | Duke Street Bio Limited | Pharmaceutical compound |
| WO2023250439A1 (en) * | 2022-06-22 | 2023-12-28 | Tempest Therapeutics, Inc. | Trex1 inhibitors and uses thereof |
| WO2024061300A1 (en) * | 2022-09-22 | 2024-03-28 | Insilico Medicine Ip Limited | Inhibitors of trex1 and uses thereof |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2007056124A2 (en) * | 2005-11-04 | 2007-05-18 | Hydra Biosciences, Inc. | Compounds for modulating trpv3 function |
| WO2009106561A1 (en) * | 2008-02-27 | 2009-09-03 | Biovitrum Ab (Publ) | Pyrazine compounds for treating gpr119 related disorders |
| CN102046608B (zh) * | 2008-06-02 | 2014-04-02 | 詹森药业有限公司 | 3,4-二氢嘧啶trpa1拮抗剂 |
| EP2482823A2 (en) * | 2009-10-02 | 2012-08-08 | Sanofi | Use of compounds with sglt-1/sglt-2 inhibitor activity for producing medicaments for treatment of bone diseases |
| WO2011107494A1 (de) * | 2010-03-03 | 2011-09-09 | Sanofi | Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung |
| EP2685982B1 (en) * | 2011-03-17 | 2017-07-05 | Bristol-Myers Squibb Company | Pyrrolopyridazine jak3 inhibitors and their use for the treatment of inflammatory and autoimmune diseases |
-
2019
- 2019-12-06 FI FIEP19828476.2T patent/FI3891145T3/fi active
- 2019-12-06 MX MX2021006695A patent/MX2021006695A/es unknown
- 2019-12-06 SG SG11202105772SA patent/SG11202105772SA/en unknown
- 2019-12-06 HU HUE19828476A patent/HUE062866T2/hu unknown
- 2019-12-06 EP EP19828476.2A patent/EP3891145B1/en active Active
- 2019-12-06 LT LTEPPCT/US2019/064825T patent/LT3891145T/lt unknown
- 2019-12-06 US US17/311,526 patent/US20220017502A1/en active Pending
- 2019-12-06 DK DK19828476.2T patent/DK3891145T3/da active
- 2019-12-06 RS RS20230531A patent/RS64336B1/sr unknown
- 2019-12-06 EA EA202191519A patent/EA202191519A1/ru unknown
- 2019-12-06 CA CA3122093A patent/CA3122093A1/en active Pending
- 2019-12-06 CN CN201980091375.4A patent/CN113396149B/zh active Active
- 2019-12-06 SI SI201930577T patent/SI3891145T1/sl unknown
- 2019-12-06 PT PT198284762T patent/PT3891145T/pt unknown
- 2019-12-06 HR HRP20230701TT patent/HRP20230701T1/hr unknown
- 2019-12-06 MA MA54386A patent/MA54386B1/fr unknown
- 2019-12-06 ES ES19828476T patent/ES2949999T3/es active Active
- 2019-12-06 BR BR112021010919-6A patent/BR112021010919A2/pt unknown
- 2019-12-06 WO PCT/US2019/064825 patent/WO2020118133A1/en unknown
- 2019-12-06 AU AU2019395005A patent/AU2019395005A1/en active Pending
- 2019-12-06 PL PL19828476.2T patent/PL3891145T3/pl unknown
- 2019-12-06 JP JP2021531909A patent/JP7471297B2/ja active Active
- 2019-12-06 PE PE2021000822A patent/PE20212070A1/es unknown
- 2019-12-06 KR KR1020217020940A patent/KR20210102310A/ko unknown
- 2019-12-06 IL IL283672A patent/IL283672B1/en unknown
-
2021
- 2021-06-03 CL CL2021001461A patent/CL2021001461A1/es unknown
- 2021-07-02 CO CONC2021/0008816A patent/CO2021008816A2/es unknown
-
2023
- 2023-07-11 CY CY20231100328T patent/CY1126082T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| SI3891145T1 (sl) | 2023-11-30 |
| AU2019395005A1 (en) | 2021-06-17 |
| MA54386B1 (fr) | 2023-08-31 |
| IL283672B1 (en) | 2024-06-01 |
| IL283672A (en) | 2021-07-29 |
| PL3891145T3 (pl) | 2023-08-07 |
| DK3891145T3 (da) | 2023-07-24 |
| HUE062866T2 (hu) | 2023-12-28 |
| JP7471297B2 (ja) | 2024-04-19 |
| SG11202105772SA (en) | 2021-06-29 |
| BR112021010919A2 (pt) | 2021-08-24 |
| CO2021008816A2 (es) | 2021-07-19 |
| EP3891145B1 (en) | 2023-04-12 |
| CY1126082T1 (el) | 2023-11-15 |
| CN113396149A (zh) | 2021-09-14 |
| JP2022510431A (ja) | 2022-01-26 |
| CL2021001461A1 (es) | 2021-12-17 |
| WO2020118133A1 (en) | 2020-06-11 |
| ES2949999T3 (es) | 2023-10-04 |
| EA202191519A1 (ru) | 2021-10-27 |
| FI3891145T3 (fi) | 2023-07-18 |
| US20220017502A1 (en) | 2022-01-20 |
| MA54386A (fr) | 2021-10-13 |
| CN113396149B (zh) | 2024-07-02 |
| RS64336B1 (sr) | 2023-08-31 |
| HRP20230701T1 (hr) | 2023-10-13 |
| EP3891145A1 (en) | 2021-10-13 |
| PT3891145T (pt) | 2023-07-18 |
| MX2021006695A (es) | 2021-09-23 |
| KR20210102310A (ko) | 2021-08-19 |
| CA3122093A1 (en) | 2020-06-11 |
| LT3891145T (lt) | 2023-08-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20212070A1 (es) | Moduladores de trex1 | |
| PE20191304A1 (es) | Modulador del regulador de conductancia de transmembrana de fibrosis quistica, composiciones farmaceuticas, metodos de tratamiento y proceso para producir el modulador | |
| PE20221339A1 (es) | Inhibidores de parp1 | |
| AR116604A1 (es) | Inhibidores de kras g12c | |
| PE20230238A1 (es) | Inhibidores de kras g12c | |
| PE20191541A1 (es) | Composiciones y metodos para inhibir la accion de la arginasa | |
| PE20190329A1 (es) | Compuestos moduladores de fxr (nr1h4) | |
| PE20230376A1 (es) | Compuestos moduladores de la diacilglicerol quinasa | |
| AR112797A1 (es) | Inhibidores de kras g12c y métodos para utilizarlos | |
| AR094784A1 (es) | Compuestos de tubulisina, métodos para obtenerlos y uso | |
| ECSP20044709A (es) | Inhibidores de sarcómero cardíaco | |
| AR085327A1 (es) | Inhibidores del virus de la hepatitis c | |
| AR086254A1 (es) | Derivados de imidazol utiles para el tratamiento de artritis | |
| CO2022008968A2 (es) | Nuevos derivados de metilquinazolinona | |
| AR101815A1 (es) | Compuestos y composiciones como inhibidores de quinasa | |
| AR081058A1 (es) | Derivados de arilmetoxi isoindolina, composiciones que los comprenden y su uso en el tratamiento del cancer. | |
| AR111315A1 (es) | Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue | |
| AR083367A1 (es) | Compuestos de tipo quinazolinona como antagonistas de crth | |
| PE20181304A1 (es) | Derivados de indol n-sustituidos como moduladores de los receptores de pge2 | |
| AR116283A1 (es) | Inhibidores del sarcómero cardíaco | |
| PE20212253A1 (es) | Compuestos de piperidina urea 4-metilsulfonil-sustituidos para el tratamiento de miocardiopatia dilatada (mcd) | |
| AR121226A1 (es) | Compuestos y usos de estos | |
| AR107030A1 (es) | Inhibidores aza-bencimidazol de pad4 | |
| CO2019004978A2 (es) | Compuestos terapéuticos y métodos para utilizarlos | |
| AR111494A1 (es) | Compuestos de anilinoquinazolina c₅ y su uso en el tratamiento del cáncer |